Andes HSG

Andes HSG is a clinical-stage biotechnology company pioneering a novel approach to cancer treatment by targeting mitochondrial non-coding RNA (ncmtRNA). The company's proprietary platform develops antisense oligonucleotides that selectively induce apoptosis in cancer cells while sparing normal cells, based on the differential expression of these RNA molecules. Their lead candidate, Andes-1537, has demonstrated safety and preliminary efficacy in Phase 1 clinical trials for advanced solid tumors. Headquartered in Chile with operations in the United States, Andes HSG aims to provide a universal, low-toxicity therapeutic solution for a wide range of oncological indications. The company's research is supported by a robust intellectual property portfolio and collaborations with leading academic institutions.